miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer / 华中科技大学学报(医学)(英德文版)
Journal of Huazhong University of Science and Technology (Medical Sciences)
; (6): 839-845, 2016.
Article
在 En
| WPRIM
| ID: wpr-238433
Responsible library:
WPRO
ABSTRACT
Gefitinib is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC). Unfortunately, most NSCLC patients inevitably develop gefitinib resistance during treatment. In addition to EGFR mutation status, the mechanisms involved are largely unknown. In this study, we showed that miR-124, a tumor suppressor, was significantly down-regulated in gefitinib-resistant NSCLC patients and cell lines compared with gefitinib-sensitive patients and cell lines. In addition, the miR-124 depletion induced gefitinib resistance, and miR-124 overexpression sensitized gefitinib-resistant cells to gefitinib. Mechanistic analysis revealed that miR-124 decreased SNAI2 and STAT3 expression by directly targeting their 3'UTRs and that knocking down SNAI2 or STAT3 partly reversed the gefitinib resistance induced by miR-124 depletion. Our data demonstrate that the miR-124 plays a new critical role in acquired resistance to gefitinib and that the manipulation of miR-124 might provide a therapeutic strategy for reversing acquired gefitinib resistance.
Key words
全文:
1
索引:
WPRIM
主要主题:
Pharmacology
/
Quinazolines
/
Carcinoma, Non-Small-Cell Lung
/
Drug Resistance, Neoplasm
/
3' Untranslated Regions
/
MicroRNAs
/
Cell Line, Tumor
/
Therapeutic Uses
/
Drug Therapy
/
STAT3 Transcription Factor
限制:
Humans
语言:
En
期刊:
Journal of Huazhong University of Science and Technology (Medical Sciences)
年:
2016
类型:
Article